Picture of Autolus Therapeutics logo

AUTL — Autolus Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-23.68%
3m-28.76%
6m-52.15%
1yr-56.38%
Volume Change (%)
10d/3m-29.82%
Price vs... (%)
52w High-68.89%
50d MA-28.2%
200d MA-49.13%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-49.8%
Return on Equity-51.13%
Operating Margin-7494.93%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Autolus Therapeutics EPS forecast chart

Profile Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on developing programmed T cell therapies for the treatment of cancer. The Company has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

Directors

    Last Annual
    December 31st, 2021
    Last Interim
    March 31st, 2022
    Incorporated
    February 2nd, 2018
    Public Since
    June 22nd, 2018
    No. of Employees
    324
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    90,907,941

    AUTL Share Price Performance

    Latest News for AUTL

    Upcoming Events for AUTL

    Autolus Therapeutics PLC To Discuss Four Clinical Data Updates at the European Hematology Association Congress Call

    Autolus Therapeutics PLC Annual Shareholders Meeting

    Similar to AUTL

    Picture of 2Seventy Bio logo

    2Seventy Bio

    us flag iconNASDAQ Global Select Market

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of ACADIA Pharmaceuticals logo

    ACADIA Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    FAQ

    Or unlock with your email

    Or unlock with your email